“The level of responsibility for young people in the Israeli army trains them for entrepreneurship and they see startups as a way to follow the Jewish idea of Tikun Olam — improving the world,” said Cukierman
“Over the past five years we have been committed to investing in core investment banking and private equity,” said Edouard Cukierman, Chairman and Founder of the Cukierman Investment Group in Israel. “We will continue to work hard to promote cross-border cooperation.”
Eloxx Pharmaceuticals, focused on the discovery, development and commercialization of compounds for the treatment of genetic diseases such as cystic fibrosis and cystinosis, received $24 million from the Israeli-Chinese Catalyst CEL Fund, Pontifax and other industry players. In May, Eloxx entered into a merger agreement with Sevion Therapeutics.
Fan, managing partner of the Israeli-Chinese Catalyst CEL Fund and head of the merger and acquisition department at China Everbright Ltd., is in Israel this week as the fund announces its latest investment in the Israeli company Eloxx Pharmaceuticals.